Results 201 to 210 of about 76,287 (256)

Effects of the glucagon-like peptide-1 receptor agonist PEG-Loxe on diabetic osteoporosis: A mechanistic study. [PDF]

Mol Metab
Zhang L, Hu J, Huang C, Gao X, Pang D, Duan L.   +5 more
europepmc   +1 more source

Compartmentalisation in cAMP signalling: A phase separation perspective

British Journal of Pharmacology, EarlyView.
Cells rely on precise spatiotemporal control of signalling pathways to ensure functional specificity. The compartmentalisation of cyclic AMP (cAMP) and protein kinase A (PKA) signalling enables distinct cellular responses within a crowded cytoplasmic space.
Milda Folkmanaite, Manuela Zaccolo
wiley   +1 more source

Effects of Glucagon-like Peptide-1 Receptor Agonists on Skin Homeostasis and Skin Aging Processes. [PDF]

J Clin Med
Žaliukaitė G, Lebbar N.
europepmc   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Glucagon-like peptide-1 agonists usage to widen the living donor pool for liver transplantation: A novel metabolic strategy. [PDF]

World J Transplant
Alnagar A, Khan MU, Ahmad MS, Mersal M, Ayyad M, Hassan R, Noormohamed MS.   +6 more
europepmc   +1 more source

Pneumatosis intestinalis in a patient treated with a glucagon-like peptide-1 receptor agonist and prednisone. [PDF]

JCEM Case Rep
Sutton S, Ferguson Q, Gimpelevich R, Hemadeh O.   +3 more
europepmc   +1 more source

Glucagon-like Peptide-1 Receptor Agonists in Rheumatoid Arthritis: A Scoping Review of Metabolic, Anti-Inflammatory, and Cardioprotective Effects. [PDF]

J Pers Med
Buonanno S, Gaggiano C, Baldi C, Cantarini L, Frediani B, Gentileschi S.   +5 more
europepmc   +1 more source

Effects of Treatment with Glucagon-like Peptide-1 Receptor Analogues on the Diabetic Foot. [PDF]

Biomedicines
Ortiz Romero M, Rodríguez de Vera Gómez D, Rodríguez de Vera Gómez P, Gordillo Fernández LM.   +3 more
europepmc   +1 more source

Glucagon-Like Peptide-1 Agonist vs. Placebo and Pulmonary Decline After Open-Heart Surgery: A Substudy of the GLORIOUS Randomised Clinical Trial. [PDF]

Acta Anaesthesiol Scand
Mikkelsen AD, Wiberg S, Schultz HHL, Møller-Sørensen PH, Høfsten D, Nilsson JC, Møller CH, Køber L, Hassager C, Kjærgaard J.   +9 more
europepmc   +1 more source